Despite recent implementation of peripartum chemoprophylaxis of carriers, Group B Streptococci (GBS) remain the leading cause of neonatal sepsis in the U.S. In addition, pregnancy-related morbidity occurs in nearly 50,000 women annually, and GBS disease among adults with immunocompromising chronic illness was recently recognized as an important cause of morbidity and mortality. Widespread use of a successful multivalent GBS conjugate vaccine could significantly alleviate the mortality and morbidity associated with this pathogen. The ultimate public health goal is the licensure of an efficacious vaccine to prevent GBS infection in those at risk, including newborn infants, postpartum women, and immunocompromised adults. Excellent progress has been made in developing vaccines against GBS disease and in understanding the epidemiology and basic biology of the organism, and the work under this renewal contract will build on this progress. While infections due to GBS have been increasing over the last thirty years, there has also been a resurgence of invasive Group A streptococcal (GAS) disease that began in the 1980s and has continued unabated. The reasons for the resurgence remain poorly understood and mandate investigations into basic pathogenic mechanisms of GAS disease in order to understand the recent changes in patterns and severity of infections and to design appropriate intervention strategies. Based on the trends in streptococcal disease, four areas have been identified as topics having the highest priority for investigation in the contract renewal period: (1) study of pathogenic mechanisms of streptococcal infections (GBS and GAS); (2) epidemiologic surveillance (GBS); (3) production and human testing of vaccines (GBS); and (4) laboratory support for vaccine trials (GBS).

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Flores, Aurea E; Chhatwal, G S; Hillier, Sharon L et al. (2014) Expression of group B protective surface protein (BPS) by invasive and colonizing isolates of group B streptococci. Curr Microbiol 69:894-8
Edwards, Morven S; Lane, Heidi J; Hillier, Sharon L et al. (2012) Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 30:4123-6
Stoner, Kevin A; Rabe, Lorna K; Austin, Michele N et al. (2011) Incidence and epidemiology of Streptococcus pseudoporcinus in the genital tract. J Clin Microbiol 49:883-6
Meyn, Leslie A; Krohn, Marijane A; Hillier, Sharon L (2009) Rectal colonization by group B Streptococcus as a predictor of vaginal colonization. Am J Obstet Gynecol 201:76.e1-7
Cherpes, Thomas L; Hillier, Sharon L; Meyn, Leslie A et al. (2008) A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis 35:78-83
Baker, Carol J; Rench, Marcia A; Paoletti, Lawrence C et al. (2007) Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 25:55-63
Manning, Shannon D; Ki, Moran; Marrs, Carl F et al. (2006) The frequency of genes encoding three putative group B streptococcal virulence factors among invasive and colonizing isolates. BMC Infect Dis 6:116
Seepersaud, Ravin; Needham, Rachel H V; Kim, Cathy S et al. (2006) Abundance of the delta subunit of RNA polymerase is linked to the virulence of Streptococcus agalactiae. J Bacteriol 188:2096-105
Palazzi, Debra L; Rench, Marcia A; Edwards, Morven S et al. (2004) Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 190:558-64
Baker, Carol J; Paoletti, Lawrence C; Rench, Marcia A et al. (2004) Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 189:1103-12

Showing the most recent 10 out of 30 publications